These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 36170375)

  • 101. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma.
    Findlay S; Nair R; Merrill RA; Kaiser Z; Cajelot A; Aryanpour Z; Heath J; St-Louis C; Papadopoli D; Topisirovic I; St-Pierre J; Sebag M; Kesarwala AH; Hulea L; Taylor EB; Shanmugam M; Orthwein A
    Blood Adv; 2023 Jul; 7(14):3485-3500. PubMed ID: 36920785
    [TBL] [Abstract][Full Text] [Related]  

  • 102. An mTORC1 to HRI signaling axis promotes cytotoxicity of proteasome inhibitors in multiple myeloma.
    Darawshi O; Muz B; Naamat SG; Praveen B; Mahameed M; Goldberg K; Dipta P; Shmuel M; Forno F; Boukeileh S; Pahima H; Hermann J; Raab MS; Poos AM; Weinhold N; Rosenbluh C; Gatt ME; Palm W; Azab AK; Tirosh B
    Cell Death Dis; 2022 Nov; 13(11):969. PubMed ID: 36400754
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy.
    Nair R; Gupta P; Shanmugam M
    Front Oncol; 2022; 12():1000106. PubMed ID: 36185202
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 105. Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
    Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG; Gupta VA; Matulis SM; Bhasin M; Lonial S; Nooka AK; Wiita AP; Boise LH; Nagrath D; Shanmugam M
    Sci Adv; 2022 Sep; 8(39):eabq5575. PubMed ID: 36170375
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
    Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D
    Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma.
    Bajpai R; Sharma A; Achreja A; Edgar CL; Wei C; Siddiqa AA; Gupta VA; Matulis SM; McBrayer SK; Mittal A; Rupji M; Barwick BG; Lonial S; Nooka AK; Boise LH; Nagrath D; Shanmugam M
    Nat Commun; 2020 Mar; 11(1):1228. PubMed ID: 32144272
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Targeting Bcl-2 for the treatment of multiple myeloma.
    Touzeau C; Maciag P; Amiot M; Moreau P
    Leukemia; 2018 Sep; 32(9):1899-1907. PubMed ID: 30076373
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression.
    Gupta VA; Barwick BG; Matulis SM; Shirasaki R; Jaye DL; Keats JJ; Oberlton B; Joseph NS; Hofmeister CC; Heffner LT; Dhodapkar MV; Nooka AK; Lonial S; Mitsiades CS; Kaufman JL; Boise LH
    Blood; 2021 Jul; 137(26):3604-3615. PubMed ID: 33649772
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax.
    Bajpai R; Matulis SM; Wei C; Nooka AK; Von Hollen HE; Lonial S; Boise LH; Shanmugam M
    Oncogene; 2016 Jul; 35(30):3955-64. PubMed ID: 26640142
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib.
    Schlesser C; Meul T; Stathopoulos G; Meiners S
    Biomolecules; 2022 May; 12(6):. PubMed ID: 35740881
    [TBL] [Abstract][Full Text] [Related]  

  • 112. The hallmarks of cancer metabolism: Still emerging.
    Pavlova NN; Zhu J; Thompson CB
    Cell Metab; 2022 Mar; 34(3):355-377. PubMed ID: 35123658
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia.
    Bosc C; Saland E; Bousard A; Gadaud N; Sabatier M; Cognet G; Farge T; Boet E; Gotanègre M; Aroua N; Mouchel PL; Polley N; Larrue C; Kaphan E; Picard M; Sahal A; Jarrou L; Tosolini M; Rambow F; Cabon F; Nicot N; Poillet-Perez L; Wang Y; Su X; Fovez Q; Kluza J; Argüello RJ; Mazzotti C; Avet-Loiseau H; Vergez F; Tamburini J; Fournié JJ; Tiong IS; Wei AH; Kaoma T; Marine JC; Récher C; Stuani L; Joffre C; Sarry JE
    Nat Cancer; 2021 Nov; 2(11):1204-1223. PubMed ID: 35122057
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Disruption of the TCA cycle reveals an ATF4-dependent integration of redox and amino acid metabolism.
    Ryan DG; Yang M; Prag HA; Blanco GR; Nikitopoulou E; Segarra-Mondejar M; Powell CA; Young T; Burger N; Miljkovic JL; Minczuk M; Murphy MP; von Kriegsheim A; Frezza C
    Elife; 2021 Dec; 10():. PubMed ID: 34939929
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Systems level profiling of chemotherapy-induced stress resolution in cancer cells reveals druggable trade-offs.
    Saavedra-García P; Roman-Trufero M; Al-Sadah HA; Blighe K; López-Jiménez E; Christoforou M; Penfold L; Capece D; Xiong X; Miao Y; Parzych K; Caputo VS; Siskos AP; Encheva V; Liu Z; Thiel D; Kaiser MF; Piazza P; Chaidos A; Karadimitris A; Franzoso G; Snijders AP; Keun HC; Oyarzún DA; Barahona M; Auner HW
    Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33883278
    [TBL] [Abstract][Full Text] [Related]  

  • 116.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 117.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.